U.S. FDA Grants IND Clearance for Aclaris’ ATI-052 Bispecific Antibody Trial
The U.S. Food and Drug Administration (FDA) has cleared Aclaris Therapeutics, Inc.’s Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a bispecific anti-Thymic Stromal Lymphopoietin (TSLP)/Interleukin-4 Receptor (IL-4R) monoclonal antibody being developed for immuno-inflammatory diseases.